Multiple Ascending Dose Phase 1 Clinical Study of Safety, Tolerability and Pharmacokinetics of CRS3123, a Narrow Spectrum Agent with Minimal Disruption of Normal Gut Microbiota.
CRS3123 is a novel small molecule that potently inhibits methionyl-tRNA synthetase of Clostridioides difficile, inhibiting C. difficile toxin production and spore formation. CRS3123 has been evaluated in a multiple ascending dose placebo-controlled Phase 1 trial. Thirty healthy subjects, ages 18 to 45, were randomized into three cohorts of 10 subjects each, receiving either 200, 400 or 600 mg of CRS3123 (eight subjects per cohort) or placebo (two subjects per cohort) by oral administration twice daily for 10 days. CRS3123 was generally safe and well tolerated with no serious adverse events (SAEs), or severe treatment-emergent adverse events (TEAEs) reported. All subjects completed their assigned treatment and follow-up visits, and there were no trends in systemic, vital signs or laboratory TEAEs. There were no QTcF interval changes or any clinically significant changes in other ECG intervals or morphology. CRS3123 showed limited but detectable systemic uptake; although absorption increased with increasing dose, the increase was less than dose proportional. Importantly, the bulk of the oral dose was not absorbed, and fecal concentrations were substantially above the MIC90 value of 1 μg/ml at all dosages tested. Subjects receiving either of the two lower doses of CRS3123 exhibited minimal disruption of normal gut microbiota after ten days of twice-daily dosing. CRS3123 was inactive against important commensal anaerobes including Bacteroides, Bifidobacteria and commensal Clostridia. Microbiome data showed favorable differentiation compared to other CDI therapeutics. These results support further development of CRS3123 as an oral agent for the treatment of CDI.